AstraZeneca pays 660% premium for gene therapy firm LogicBio

Shares of LogicBio Therapeutics skyrocketed on Monday after Britain’s AstraZeneca’s said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million. LoigBio’s shares, which have traded below $1 since February, were up 637% at $2 before the bell, close to AstraZeneca’s offer price of $2.07 per share. LogicBio is […]